Critical Analysis: Vycor Medical (OTCMKTS:VYCO) versus CVRx (NASDAQ:CVRX)

Vycor Medical (OTCMKTS:VYCO) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Volatility and Risk

Vycor Medical has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Insider & Institutional Ownership

75.3% of CVRx shares are owned by institutional investors. 7.0% of Vycor Medical shares are owned by company insiders. Comparatively, 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Vycor Medical and CVRx’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vycor Medical	$1.46 million	1.97	-$70,000.00	N/A	N/A
CVRx	$44.39 million	4.09	-$41.20 million	($2.47)	-3.40

Vycor Medical has higher earnings, but lower revenue than CVRx.

Profitability

This table compares Vycor Medical and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vycor Medical	-7.49%	N/A	-10.32%
CVRx	-122.52%	-72.51%	-49.78%

Analyst Ratings

This is a summary of recent ratings and target prices for Vycor Medical and CVRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vycor Medical	0	0	0	0	N/A
CVRx	0	2	4	0	2.67

CVRx has a consensus price target of $13.60, indicating a potential upside of 61.90%. Given CVRx’s higher possible upside, analysts plainly believe CVRx is more favorable than Vycor Medical.

Summary

CVRx beats Vycor Medical on 7 of the 11 factors compared between the two stocks.

About Vycor Medical

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.